国药一致(000028) - 2025 Q3 - 季度财报

Financial Performance - The company reported a revenue of CNY 18.33 billion for Q3 2025, a decrease of 1.89% year-on-year, and a total revenue of CNY 55.12 billion for the first nine months, down 2.38% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 291.21 million, a decline of 9.58% year-on-year, with a total net profit of CNY 957.12 million for the first nine months, down 10.18% year-on-year[5] - Basic earnings per share for Q3 2025 decreased by 10.34% to CNY 0.52, while the diluted earnings per share remained the same at CNY 0.52[5] - Total operating revenue for the third quarter was CNY 55,124,490,690.34, a decrease of 2.4% from CNY 56,466,354,478.37 in the previous year[18] - Net profit for the period was CNY 1,019,397,384.05, a decline of 6.9% compared to CNY 1,095,669,310.29 in the same period last year[19] - Earnings per share decreased to CNY 1.72 from CNY 1.91, reflecting a 9.9% drop[19] Segment Performance - The distribution segment achieved a revenue of CNY 40.59 billion in the first nine months, a decrease of 0.59%, with a net profit of CNY 72.30 million, down 7.32% year-on-year[5] - The retail segment, represented by Guoda Pharmacy, reported a revenue of CNY 15.23 billion, a decline of 7.14%, but net profit increased by 133.91% to CNY 1.30 million[5] Assets and Liabilities - Total assets at the end of the reporting period were CNY 50.56 billion, an increase of 6.31% from the previous year[5] - Total liabilities rose to CNY 29,013,188,938.82, compared to CNY 26,800,461,097.40, indicating an increase of 8.2%[17] - The company's equity attributable to shareholders increased to CNY 18,429,946,171.49 from CNY 17,669,528,375.65, a growth of 4.3%[17] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY 463.08 million for the first nine months, a decline of 136.15% year-on-year[5] - Operating cash flow for the current period is -463,076,420.41 CNY, a decrease from 1,281,092,108.09 CNY in the previous period, indicating a significant decline in operational performance[21] - Total cash inflow from operating activities is 55,641,036,328.40 CNY, down from 56,625,996,162.02 CNY year-over-year[21] - Cash outflow from operating activities increased to 56,104,112,748.81 CNY from 55,344,904,053.93 CNY, reflecting higher operational costs[21] Investment and Financing Activities - Cash inflow from financing activities reached 1,566,290,860.14 CNY, compared to 1,410,753,157.68 CNY in the previous period, reflecting a stronger capital raising effort[21] - Cash flow from financing activities increased by 672.37 million yuan, a growth rate of 33.85%, primarily due to an increase in bank borrowings[11] Shareholder Information - Total number of common shareholders at the end of the reporting period is 41,385[13] - The largest shareholder, China National Pharmaceutical Group Corporation, holds 56.06% of shares, totaling 311,999,988 shares[13] - The top ten shareholders hold a significant portion of shares, with the top shareholder alone holding over half of the total[13] Other Financial Metrics - The weighted average return on equity decreased by 0.70 percentage points to 5.29% for the first nine months[5] - Research and development expenses were CNY 16,559,803.77, down from CNY 19,243,795.36, a decrease of 13.9%[18] - The company reported an investment income of CNY 165,074,116.96, down from CNY 254,930,911.72, a decline of 35.2%[18]